Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

Insmed's Brensocatib has received its first approval as a treatment for non cystic fibrosis bronchiectasis. The product ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the ...

This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...

Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

Please provide your email address to receive an email when new articles are posted on . Indigenous ethnicity and new abnormal auscultatory signs raised the odds for symptom resolution after antibiotic ...

Notable signs and symptoms distinguishing bronchiectasis from other pulmonary disease states are discussed. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the ...

The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...

Learn how bronchiectasis affects more than just your lungs, from heart health and bone density to mental well-being and cognitive risks.

A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...